2010 AnnuAl REpoRT - Ciberdem

CIBERDEM Projects
Introduction
CIBERDEM seeks to achieve scientific excellence in
research and encourage bench-to-bed as well as bed-tobench
transition (see figures 1 and 2). In order to achieve
these goals it promotes collaboration between basic and
clinical research groups to prioritize translational research
in the network. To this end, 14 initiatives based mainly on
diabetes and its complications planned to last a year and
a half have been instituted. CIBERDEM forges synergies
between its members and launches initiatives that can offer
an attractive opportunity to build up collaborations with
other centres outside the consortium, whether national or
international, because these projects can be seen as a
pool of scientific knowledge that involves several Spanish
research groups of excellence in diabetes at the same time.
Objectives
To develop scientific actions focused on diabetes and its
metabolic disorders with a high impact on research.
To improve collaborations among CIBERDEM researchers,
mainly among clinical and basic research groups (with a
minimum participation of 3 research groups at any one time).
To forge alliances between CIBERDEM researchers through
joint work on the design and implementation of the projects.
To demonstrate the competitiveness of CIBERDEM researchers
and the innovation of their collaborative projects.
To establish initiatives that a single CIBERDEM research
group can not embark upon alone.
Achievements in 2010
14 CIBERDEM initiatives were implemented during 2009-
2010. The Scientific Director and the Management Office
followed these projects scientifically and managerially
right from the outset and the researchers involved in
the translational research actions worked hard in order
to achieve successful scientific outputs which were
disseminated both within and outside CIBERDEM.
At the CIBERDEM Annual Meeting in 2010, nearly 25% of the
total oral presentations made focused on the explanation of both
the work performed and the results obtained in the 14 actions.
CIBERDEM Projects were also made known to the
wider national and international scientific community.
In this regard, oral presentations were made at several
congresses worldwide. Moreover, many original articles
were published in international peer review journals such
as Endocrinology, PNAS, Diabetology and The Journal of
Clinical Endocrinology and Metabolism (JCEM).
The merits resulting from the 14 CIBERDEM Projects are
included in this 2010 Annual Report and can be seen in the
research outcomes of each research group participating
in the initiatives.
Future challenges
In 2011 CIBERDEM aims to continue exploiting the results
already obtained with the objective of demonstrating the
impact of the investment that the consortium has made
in the collaborative translational activity of their research
groups. During the coming year, the Scientific Director and
the Managing Director will work together to obtain additional
Clinical research groups Basic research groups
funding to continue with these initiatives, hopefully at the
STEMOB
3 5
same level, MODIABor at
1
least to a
3
similar extent. The expected
desirable LOWHDL aim is to 2be able to sustain 3 the contribution of
IODURE 1 4
these INGENFRED actions to the scientific
3
prestige
1
of the institution. It is
important ENDODIAB not to forget 2 that 1the 14 CIBERDEM translational
DOTUM 1 2
research
DIASOBS
projects have increased
4
the
1competitiveness of
the CHILDBODYFAT activity of the centre, 2 providing 1 CIBERDEM with more
opportunities for obtaining funding in the near future,
from both the public and private sectors, always with the
objective of assigning it to CIBERDEM diabetes research.
NEURONET-DIAB
METADIAB
IREVAS
GIDIPRED
ANTIBETACELL
Basic research groups
Clinical research groups
2 1
1 2
2 1
1 2
2 1
Figure 1. CIBERDEM bench to bed projects (NEURONET-DIAB,
METADIAB, IREVAS, GIDIPRED, ANTIBECELL) showing the number
of research groups participating in each project (in green the
groups with a basic profile, in red those with a clinical profile).
STEMOB
MODIAB
LOWHDL
IODURE
INGENFRED
ENDODIAB
DOTUM
DIASOBS
CHILDBODYFAT
Clinical research groups
3 5
1 3
2 3
1 4
3 1
2 1
1 2
4 1
2 1
Basic research groups
Figure 2. CIBERDEM bed to bench projects (STEMOB, MODIAB,
LOWHDL, IODURE, INGENFRED, ENDODIAB, DOTUM, DIASOBS,
CHILDBODYFAT) showing the number of research groups participating
in each project (in red the groups with a clinical profile, in
green those with a basic profile).
Basic research groups Clinical research groups
NEURONET-DIAB
METADIAB
IREVAS
GIDIPRED
ANTIBETACELL
2 1
1 2
2 1
1 2
2 1
2010 Annual Report
23